Name | BD-1047 (dihydrobromide) |
Synonyms | 169592 BD-1047 BD 1047 BD1047 HBr BD 1047 HBr BD 1047 (hydrobromide) BD-1047 (dihydrobromide) N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide n-[2-(3,4-dichlorophenyl)ethyl]-n,n',n'-trimethylethane-1,2-diamine dihydrobromide 1,2-ethanediamine, N-[2-(3,4-dichlorophenyl)ethyl]-N,N',N'-trimethyl-, dihydrobromide |
CAS | 138356-21-5 |
Molecular Formula | C13H22Br2Cl2N2 |
Molar Mass | 437.04118 |
Solubility | DMSO: 36 mg/mL( < 1 mg/ml refers to the product slightly soluble or insoluble) |
Appearance | powder |
Color | white |
Storage Condition | Inert atmosphere,2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. |
Use | BD1047 is a potent and selective Sigma-1 Receptor Antagonist. It has effects in animal studies suggestive of antipsychotic activity and may also be useful in the treatment of neuropathic pain. BD-1047 has >50-fold selectivity at σ1 over σ2 and also >100-fold selectivity over opiate, phencyclidine, muscarinic, dopamine, α1- & α2-adrenoceptor, 5-HT1, and 5-HT2. |
In vitro study | BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells. BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity. |
Hazard Symbols | Xi - Irritant |
Risk Codes | R37/38 - Irritating to respiratory system and skin. R41 - Risk of serious damage to eyes |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. |
WGK Germany | 3 |
Reference Show more | 1: Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015;2015:265056. doi: 10.1155/2015/265056. Epub 2015 Nov 30. PubMed PMID: 26696751; PubMed Central PMCID: PMC4677253. 2: Jeong YC, Son JS, Kwon YB. The spinal antinociceptive mechanism determined by systemic administration of BD1047 in zymosan-induced hyperalgesia in rats. Brain Res Bull. 2015 Oct;119(Pt A):93-100. doi: 10.1016/j.brainresbull.2015.07.006. Epub 2015 Oct 1. PubMed PMID: 26434709. 3: Yoon SY, Kang SY, Kim HW, Kim HC, Roh DH. Clonidine Reduces Nociceptive Responses in Mouse Orofacial Formalin Model: Potentiation by Sigma-1 Receptor Antagonist BD1047 without Impaired Motor Coordination. Biol Pharm Bull. 2015;38(9):1320-7. doi: 10.1248/bpb.b15-00183. PubMed PMID: 26328487. 4: Su DA, Jiang RY, Liu N, Ding LC, Wang DM, Yu HY, Yan ES, Zhu MH, Zhu B. Effects of BD1047, a σ(1) receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells. Exp Ther Med. 2014 Feb;7(2):435-438. Epub 2013 Dec 5. PubMed PMID: 24396420; PubMed Central PMCID: PMC3881039. 5: Roh DH, Yoon SY. Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model. Biol Pharm Bull. 2014;37(1):145-51. Epub 2013 Oct 24. PubMed PMID: 24152609. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.288 ml | 11.441 ml | 22.881 ml |
5 mM | 0.458 ml | 2.288 ml | 4.576 ml |
10 mM | 0.229 ml | 1.144 ml | 2.288 ml |
5 mM | 0.046 ml | 0.229 ml | 0.458 ml |